Literature DB >> 32414746

Combination of ceftaroline and daptomycin as treatment for complicated osteomyelitis.

Ana Gascón1, Marta Castresana2, Natalia Alzueta3, Marta Marin2, María Pío2, Aitziber Echeverria4.   

Abstract

Osteomyelitis is an infection involving bone. Staphylococcus aureus is the pathogen most frequently implicated; less frequently involved are other gram-positive organisms, such as Staphylococcus epidermidis, and also gram-negative organisms. The antibiotic of choice for treatment of osteomyelitis caused by methicillin-resistant staphylococci (MRS) is vancomycin, although other alternatives such as daptomycin or teicoplanin are also considered. Osteomyelitis caused by MRS can be difficult to treat safely and effectively. This case report describes the successful use of daptomycin combined with ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant S. epidermidis (MRSE) in a 54-year-old woman, emphasising the clinical pharmacist's role in antimicrobial stewardship programmes. This alternative combination has been studied in the treatment of methicillin-resistant S. aureus (MRSA), but it may also be useful in MRSE. © European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  hospital pharmacy education; infection control; microbiological control; microbiology; pharmacokinetics and dynamics

Mesh:

Substances:

Year:  2020        PMID: 32414746      PMCID: PMC8403780          DOI: 10.1136/ejhpharm-2019-002183

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  18 in total

Review 1.  Mechanisms of resistance to daptomycin in Staphylococcus aureus.

Authors:  N Gómez Casanova; M Siller Ruiz; J L Muñoz Bellido
Journal:  Rev Esp Quimioter       Date:  2017-10-25       Impact factor: 1.553

Review 2.  Coagulase-negative staphylococci.

Authors:  Karsten Becker; Christine Heilmann; Georg Peters
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

3.  Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.

Authors:  Brian J Werth; George Sakoulas; Warren E Rose; Joseph Pogliano; Ryan Tewhey; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

Review 4.  Antibiotic treatment of gram-positive bone and joint infections.

Authors:  Elizabeth S R Darley; Alasdair P MacGowan
Journal:  J Antimicrob Chemother       Date:  2004-04-29       Impact factor: 5.790

Review 5.  Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael J Rybak; Ben M Lomaestro; John C Rotschafer; Robert C Moellering; William A Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Pharmacotherapy       Date:  2009-11       Impact factor: 4.705

6.  Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.

Authors:  Warren E Rose; Lucas T Schulz; David Andes; Rob Striker; Andrew D Berti; Paul R Hutson; Sanjay K Shukla
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

7.  The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.

Authors:  Katie E Barber; Brian J Werth; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2014-09-22       Impact factor: 5.790

8.  Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Matthew Geriak; Fadi Haddad; Khulood Rizvi; Warren Rose; Ravina Kullar; Kerry LaPlante; Marie Yu; Logan Vasina; Krista Ouellette; Marcus Zervos; Victor Nizet; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

9.  Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry.

Authors:  K Malizos; J Sarma; R A Seaton; M Militz; F Menichetti; G Riccio; J Gaudias; U Trostmann; R Pathan; K Hamed
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-11-13       Impact factor: 3.267

Review 10.  Enhancing pharmacists' role in developing countries to overcome the challenge of antimicrobial resistance: a narrative review.

Authors:  M H F Sakeena; Alexandra A Bennett; Andrew J McLachlan
Journal:  Antimicrob Resist Infect Control       Date:  2018-05-02       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.